Navigation Links
Smooth sailing: 'cruise ship virus' tackled by UH, Baylor College of Medicine

e through the creation of a quick, accurate test for the "Cruise Ship Virus." One of the difficulties in treating Norwalk is that it is very hard to diagnose with traditional methods.

"The current tests take a long time," Ruchhoeft said. "If we can build a diagnostic tool that mimics something like the pregnancy test in speed and ease of use, we could create a platform for rapid detection of this virus and other pathogens."

The tool Ruchhoeft and Willson are building will rely on the disease protein/antibody relationship that occurs in the human body. As with all diseases, when an individual is infected with the Norwalk virus, the human immune system creates antibody proteins that bond only with proteins that are specific to that disease.

Under Ruchhoeft and Willson's plan, a biological sample from a suspected Norwalk victim will be placed on a glass slide covered with Norwalk antibodies provided by BCM. An attempt will be made to wash away the sample, but if the virus is present in the sample, it will bond with the antibody and remain on the slide.

The next step of the test relies on retroreflectors, specially designed cubes that reflect light back to its point of origin, that are used on the macroscale for items such as reflective vests and lane markers on roads. Ruchhoeft, however, will create retroreflectors that measure just a few micrometers wide.

Three sides of the reflectors will be covered with reflective material and will be populated with the Norwalk antibody. These retroreflectors will be dispensed onto the slide. If Norwalk is present on the slide from the previous protein/antibody bond, the retroreflectors will bond with it. If not, they will all be washed away when the slide is rinsed.

An optical device will then shine a strong light on the slide. If, due to the protein/antibody bond, the retroreflectors remain on the slide, they will clearly reflect the light, indicating the p
'"/>

Source:University of Houston


Page: 1 2 3

Related biology news :

1. Clue found to Epstein-Barr virus ability to form and sustain tumors
2. Protecting virus offers instant flu protection and converts flu infections into their own vaccines
3. Cancer cells suppress large regions of DNA by a reversible process that can be tackled
4. Genpathway and Baylor College of Medicine Identify New Genes in Breast Cancer
5. Researcher at UGA College of Veterinary Medicine identifies new way of combating viral diseases
6. Williams College biologist explores photosynthetic apparatus
7. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
8. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
9. $6.5 Million Grant for Microarray Center at Yale School of Medicine
Post Your Comments:
(Date:12/3/2009)... of this message: , , Preliminary Press ... California Academy of Sciences museum, Attention PIOs: Sending ... registration deadline 10 December, News Media registration ... THIS MONDAY, 7 December, Who,s coming, , ...
(Date:12/3/2009)... Rapids, Mich. (Dec. 3, 2009) Van Andel ... hormone abscisic acid (ABA) works at the molecular level to ... cold. Their findings, published in the journal Nature ... around the world and combat global food shortages. The ...
(Date:12/3/2009)... of the upcoming forest deal at Copenhagen in order to ... University of Leeds. , Writing today in Nature ... the carbon credit payments to be agreed at Copenhagen, known ... made to forest dwellers directly, and their property rights assured. ...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 1Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 3Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 4Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 5Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 6Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 7Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 8Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 9Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 10Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 11Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 12Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 13Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 14Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 15ProAssurance Reports Second Quarter 2009 Results 53542 1ProAssurance Reports Second Quarter 2009 Results 53542 2ProAssurance Reports Second Quarter 2009 Results 53542 3ProAssurance Reports Second Quarter 2009 Results 53542 4ProAssurance Reports Second Quarter 2009 Results 53542 5ProAssurance Reports Second Quarter 2009 Results 53542 6ProAssurance Reports Second Quarter 2009 Results 53542 7ProAssurance Reports Second Quarter 2009 Results 53542 8ProAssurance Reports Second Quarter 2009 Results 53542 9ProAssurance Reports Second Quarter 2009 Results 53542 10ProAssurance Reports Second Quarter 2009 Results 53542 11ProAssurance Reports Second Quarter 2009 Results 53542 12ProAssurance Reports Second Quarter 2009 Results 53542 13
... by the University of Colorado at Boulder reveals that ... source of fine, organic particle pollutants that contribute to ... Angeles region. , According to the study, a much ... is directly emitted by vehicles and industrial processes. Instead, ...
... 24, 2008) Self-guided treatment for depression could ... , Scientists with the National Space Biomedical Research ... that will assist astronauts in recognizing and effectively ... pose a substantial threat to crew safety and ...
... release is available in German . , ... and molluscs more than plants. This is the finding of ... Research (UFZ), TU Berlin, the German Federal Institute of Hydrology ... of observations before and after the Elbe floods of August ...
Other Biology News:CU-Boulder study suggests air quality regulations miss key pollutants 2Coming soon: Self-guided, computer-based depression treatment 2Coming soon: Self-guided, computer-based depression treatment 3Vegetation hardly affected by extreme flood events 2
(Date:12/3/2009)... SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... last patient visit in its Phase 2 FDG-PET clinical ... 52 patients and was carried out at five sites ...
(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). ... stock in an amount per share equal to the quotient ...
(Date:12/2/2009)... Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ... of its fourth quarter and fiscal year 2009 on December ... Following the release, at 4:45 p.m. ET Martek will conduct ... All interested parties may listen to the call live via ...
(Date:12/2/2009)... Dec. 2 Reportlinker.com announces that a ... its catalogue: ,, Carbondioxide Incubators - ... http://www.reportlinker.com/p0164368/Carbondioxide-Incubators---A-Global-Market-Perspective.html ,, Incubators are the ... cancer, research, and other applications for providing ...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... patient recruitment for its Phase 2 trial in ... linked to doxorubicin. The decision to enter the ...
... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... the extracellular matrix, today announced it has ... human hyaluronidase enzyme,(rHuPH20) co-formulations with Humulin(R) R ... lispro) in Type 1 diabetic,patients. This study ...
... Deploys Clustered Storage to Help Redefine the ... Economics of Large-Scale Sequencing, SEATTLE, ... storage, today announced that Complete,Genomics, the world,s first provider of ... of Isilon IQ clustered,storage to unify its vast stores of ...
Other Biology Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 2Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 3
... The FilterMate is a compact, versatile system ... a 96- or 24-well microplates into a ... microplate liquid scintillation and gamma counter. The ... samples for applications such as cell proliferation, ...
... single use spatulas have been designed to ... are for those interested in eliminating the ... Each spatula is individually packaged, RNase/DNase free, ... is a new product number, created to ...
... Progesterone Receptor (PR) Competitor Assay Kits ... novel progesterone receptor binding compounds using ... utilizes a fusion of glutathione transferase ... human progesterone receptor [PR-LBD(GST)] and a ...
... combine the proven features of the pET, ... provides all of the benefits and versatility ... backbone. The pTriEx vectors have been extensively ... in all three expression systems. In each ...
Biology Products: